Jay Liu, PhD has joined the Southern Research Drug Discovery division as director of technology development and innovation. Liu will seek to expand Southern Research's drug discovery capabilities in areas that include biologics and monoclonal antibodies. He will also strive to advance projects already in Southern Research's drug discovery pipeline.
"I want to push these projects forward so that a pharmaceutical company or venture capitalist investors will want to work with us to deliver a commercial product," Liu said.
Before joining Southern Research, Liu served as CEO of China's Nanjing Galaxy Biotech and Suzhou Galaxy Biopharma, where he directed a team of around 70 scientists.
In 2010, he co-founded China's Rugen Therapeutics where he formed alliances with research organizations around the world while building a drug discovery capability that targeted central nervous system diseases. During his tenure, the Rugen team developed several candidate drugs that were licensed for clinical evaluation as treatments for autism and bipolar disorders.
In 1995, Liu started his career in the U.S. pharmaceutical industry, which included jobs at Merck and AstraZeneca. During this time, he led teams that delivered five investigational new drugs, two of which completed Phase II clinical studies. Liu holds a doctorate in pharmacology from the State University of New York at Buffalo and also studied at the Chinese Academy of Sciences and the University of California. He received postdoctoral training at the National Institutes of Health.
He has published more than 30 research papers and has filed 10 patent applications.